TANDEM-IRI-TACE combined with systemic FOLFIRI for colorectal liver metastases after oxaliplatin regimen failure: Phase I dose escalation study
Phase 1
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000015367
- Lead Sponsor
- Radiology, Nara Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1 Previous pancreato-biliary surgery or post endoscopic sphincteropapillotomy 2. Serious complications 3. Concomitant malignancy 4. A history of allergy to iodine containing agents or contrast media, irinotecan and 5FU 5. Presence of remarkable AP shunts or AV shunts 6. UGT1A1 6, UGT1A1 28
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dose Limiting Toxicity,Recommended Dose
- Secondary Outcome Measures
Name Time Method pharmacokinetics of irinotecan, tumor response, progression free survival, overall survival